Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The ZEUS trial's anti-inflammatory drug ziltivekimab struck out against heart disease, but cardiologists aren't ready to abandon the inflammation theory. The IL-6 blocker reduced inflammatory markers but had virtually no effect on major cardiovascular events (HR 0.99). Experts say the target was just too far downstream — and the search for broader anti-inflammatory strategies continues.
The phase III ZEUS trial delivered a disappointing result: ziltivekimab, Novo Nordisk's investigational IL-6 inhibitor, failed to reduce major adverse cardiovascular events (MACE) in over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease, and elevated inflammation — despite meaningfully lowering IL-6 and hs-CRP levels. Some interpreted this as a blow to the inflammatory hypothesis of ASCVD, but leading experts aren't convinced.
Proponents argue that IL-6 sits too far downstream in a complex, redundant inflammatory cascade to be an effective single target. They point to prior successes — canakinumab (CANTOS) and colchicine (COLCOT, LoDoCo2) — both of which act upstream and across multiple pathways, as proof that the hypothesis still holds. The lesson, they say, mirrors the early days of lipid-lowering therapy: early failures with narrow agents eventually gave way to statins and PCSK9 inhibitors.
By the Numbers:
Why it matters: The ZEUS result reshapes — but doesn't end — the quest to treat cardiovascular inflammation. Experts are calling for broader-acting anti-inflammatory agents and better biomarkers beyond hs-CRP to identify who will truly benefit from treatment.
